Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability

The objective of the study reported here was to describe dose equivalence and hemoglobin (Hb) stability in a cohort of unselected hemodialysis patients who were switched simultaneously from epoetin alfa to darbepoetin alfa. This was a multicenter, observational, retrospective study in patients aged...

Full description

Saved in:
Bibliographic Details
Published in:International journal of nephrology and renovascular disease 2014-01, Vol.7 (default), p.353-359
Main Authors: Arrieta, Javier, Moina, Iñigo, Molina, José, Gallardo, Isabel, Muñiz, María Luisa, Robledo, Carmen, García, Oscar, Vidaur, Fernando, Muñoz, Rosa Inés, Iribar, Izaskun, Aguirre, Román, Maza, Antonio
Format: Article
Language:English
Subjects:
Aluminum
Anemia
Care and treatment
Chronic kidney failure
Clinical medicine
Comparative analysis
Darbepoetin alfa
Erythropoietin, Recombinant
Health aspects
Hemodialysis
Hemoglobin
Iron
Kidney diseases
Original Research
Patients
Peritoneal dialysis
Proteins
Risk factors
Standard deviation
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of the study reported here was to describe dose equivalence and hemoglobin (Hb) stability in a cohort of unselected hemodialysis patients who were switched simultaneously from epoetin alfa to darbepoetin alfa. This was a multicenter, observational, retrospective study in patients aged ≥18 years who switched from intravenous (IV) epoetin alfa to IV darbepoetin alfa in October 2007 (Month 0) and continued on hemodialysis for at least 24 months. The dose was adjusted to maintain Hb within 1.0 g/dL of baseline. We included 125 patients (59.7% male, mean [standard deviation (SD)] age 70.4 [13.4] years). No significant changes were observed in Hb levels (mean [SD] 11.9 [1.3] g/dL, 12.0 [1.5], 12.0 [1.5], and 12.0 [1.7] at Months -12, 0, 12 and 24, respectively, P=0.409). After conversion, the erythropoiesis-stimulating agent (ESA) dose decreased significantly (P
ISSN:1178-7058
1178-7058
DOI:10.2147/IJNRD.S61895